Novo Nordisk Rebrands Wegovy as Lifestyle Drug — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk has dropped the terms "weight management" and "anti-obesity" for Wegovy on its website, rebranding the drug simply as a "weight loss" product
- Novo Nordisk's global ad campaigns now feature lifestyle slogans like "Live lighter" and "Summer Glow Up," reflecting the company's pivot toward general wellness appeal
- Novo Nordisk has shifted its vocabulary for people who take its drugs from "patients" to "customers," underscoring a consumer rather than clinical identity
- Novo Nordisk, described in the piece as the pioneer of the GLP-1 field, has leaned furthest into this rebranding as competitors eye the same lucrative lifestyle market
Why it matters: Novo Nordisk's language swap — from "patients" to "customers" and from "anti-obesity" to "weight loss" — signals that the GLP-1 market's biggest player is chasing the far larger pool of people who want to look and feel better, not just the clinical population with obesity, potentially reshaping who pays for these drugs and how insurers cover them.
Ask SkimNews
